CFY Biomedicals Inc.
This article was originally published in Start Up
Executive SummarySan Diego-based CFY Biomedicals Inc. believes it has the technological wherewithal to create a cure and/or preventive for the common cold. It's betting on antibody-based products that block the receptor which most forms of human rhinovirus (HRV) use to enter and infect nasal epithelial cells.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.